WB, IHC-Pmore details Unsuitable for:
Flow Cyt,ICC or IP
Synthetic peptide within Human EFEMP2 aa 400-500. The exact sequence is proprietary.
JAR and SW480 cell lysates, Human fetal lung lysate, Human breast carcinoma and muscle tissues.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Is unsuitable for Flow Cyt,ICC or IP.
Involvement in disease
Defects in EFEMP2 are a cause of cutis laxa autosomal recessive type 1 (ARCL1) [MIM:219100]. Hereditary cutis laxa refers to a heterogeneous group of connective tissue disorders characterized by cutaneous abnormalities and variable systemic manifestations. The most constant clinical feature is loose skin, sagging over the face and trunk. Hereditary cutis laxa is inherited in both autosomal dominant and autosomal recessive modes. ARCL1 shows the most severe phenotype and has the poorest prognosis. In addition to the skin, internal organs enriched in elastic fibers, such as the lung and arteries, are affected.
Belongs to the fibulin family. Contains 6 EGF-like domains.
Wang T et al. Fibulin-4 is associated with prognosis of endometrial cancer patients and inhibits cancer cell invasion and metastasis via Wnt/ß-catenin signaling pathway. Oncotarget8:18991-19012 (2017).
Read more (PubMed: 28177909) »
Zhang D et al. Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway. Int J Oncol50:1513-1530 (2017).
IHC-P, ICC/IF, WB
Read more (PubMed: 28339091) »